Spectrum of Haematological malignancies managed at tertiary centre: A one-year retrospective review

Anjan Shrestha¹, Shovana Thapa¹, Usha Mnandhar¹, Gita Sayami², Pradeep K Shrestha², Yogendra P Singh³

¹ Department of Pathology, Institute of Medicine, Tribhuwan University Teaching Hospital, Nepal
² Department of Medicine, Institute of Medicine, Tribhuwan University Teaching Hospital, Nepal
³ Department of Surgery, Institute of Medicine, Tribhuwan University Teaching Hospital, Nepal

Correspondence: Dr. Anjan Shrestha, Department of Pathology, Institute of Medicine, Tribhuwan University Teaching Hospital, Nepal.

Abstract

Introduction: Hematological malignancies are not uncommon and all ages and genders are affected. Hematological malignancies are a group of cancers that arise from a malignant transformation of cells of the bone marrow or lymphatic system. There are several classification systems for Hematological Malignancies. The WHO classification was the first worldwide consensus classification on hematological tumors.

Methods: We retrospectively collected data from the Department of Pathology and Hematology Unit of Internal medicine from 2015 to 2016. Hematological malignancies were analyzed clinically and with laboratory parameters. They were initially analyzed with complete blood counts and peripheral smear and diagnosed on the basis of Bone marrow morphological assessment, Immunophenotyping and cytogenetic and molecular markers and histopathology and Immunohistochemistry of Excised lymph node when applicable. Plasma cell dyscrasias were assessed clinically for features of CRAB (hypercalcemia, renal impairment, anemia and lytic lesion) and evaluation was done by hemogram, biochemical parameters and skeletal survey. Later plasma cell dyscrasias was diagnosed on the basis of bone marrow study, Immunofixation electrophoresis, serum free light chain assay, serum protein electrophoresis and myeloma defining events.

Results: There were 110 cases of hematological neoplasm from Feb 2015 till Jan 2016. Lymphoid neoplasm was the commonest hematological malignancies with 60.9% followed by myeloid neoplasm of 37.3% then histiocytic neoplasm of 1.5%. Median age at diagnosis for all Hematological malignancies was 55 years of age. In patients under 20 years of age, T ALL and LCH accounted each with 0.9%. In young adult Patient, NHL was the most common HM whereas; MPN was the most common HM in adults. In older patients, PCN was the most common HM.

Male were more prevalent than female in Hematological malignancies. Male accounted for 73.6% and female were 26.4% with male female ratio 2.7:1. In both male and female, Lymphoid Neoplasm was most frequent HM. In male PCN was the most frequent HM. In female, NHL, PCN and MPN was the most frequent HM.

Lymphoid neoplasm included Mature B cell Neoplasm (MBCN) 43.6%, Acute Lymphoblastic Leukemia (ALL) 7.3%, Hodgkins Lymphoma (HL) 5.5% and Mature T cell Neoplasm (MTCN) 3.6%. Plasma cell Neoplasm (PCN) (29%) was the commonest lymphoid neoplasm. Among the myeloid neoplasm (MN), Myeloproliferative neoplasm (MPN) accounted 19.1% followed by acute myeloid leukemia (AML) with 14.5% then Myelodysplastic syndrome (MDS) 4.5%. Chronic Myeloid Leukemia (CML) is the commonest HM among different subtypes of MPN.

Conclusion: HM can occur at any age group with median age at diagnosis of 55 years. Overall men are more affected with HM than women. In both male and female Lymphoid malignancies are frequent HM. There is difference in distribution pattern and subtypes of Hematological malignancies at different age group.

Keywords: Haematological malignancies; Lymphoid neoplasm; Myeloid neoplasm.
Introduction

Hematological malignancies (HM) are not uncommon in our country. All ages and genders are affected. 1 Hematological Malignancies are a group of cancers that arise from a malignant transformation of cells of the bone marrow or lymphatic system. 2 There are several classification systems for Hematological Malignancies. The 2001 WHO classification was the first worldwide consensus classification on hematological tumors. The classification is based on information such as clinical, morphologic, biologic, immunophenotypic and genetic features. 3,4,5 In 2008, as part of series of Classification of Tumours ‘blue book’ monographs (4th edition), the WHO published a new classification for hematopoetic and lymphoid neoplasm in collaboration with society for Hematopathology and the European Association for Haematopathology. In 2014, a clinical advisory committee (CAC) proposed revisions to fourth edition of classification. So, In view of recently identified molecular features, improvisation of morphological features and integrated approach, fourth edition is being updated in 2016.5,6 Lymphoid Neoplasm are classified as Mature B cell Neoplasm (MBCN), mature T and NK cell Neoplasm (MTCN), Post transplant Lymphoproliferative Disorders, Hodgkins Disease (HL) and Histiocytic and dendritic Cell Neoplasm (HDN). Myeloid Neoplasm are classified as Myeloproliferative Neoplasms (MPN), Myeloid/Lymphoid Neoplasms with eosinophilia with rearrangement, Myelodysplastic/Myeloproliferative Neoplasms, Myelodysplastic Syndrome (MDS), Acute myeloid Leukemia with related neoplasms(AML), blastic plasmacytoid dendritic cell Neoplasms, Acute Leukemia with ambiguous lineage, B and T lymphoblastic Lymphoma/Leukemia (ALL).5,6

In Institute of Medicine, Maharajgunj Medical Campus, Kathmandu, Nepal, there is no database on hematological cancers. After initiation of Haemato-oncology unit in the year 2015 analysis of Hematological malignancies in the Institute was conducted.

Methods

We retrospectively collected data from the Department of Pathology and Hematology Unit of Internal medicine from 2015 to 2016. Hematological malignancies were analyzed clinically and with laboratory parameters. Patients diagnosed as Leukemia, Myeloproliferative Neoplasm and Myelodysplastic Syndrome were initially analyzed with complete blood counts and peripheral smear and diagnosed on the basis of Bone marrow morphological assessment, Immunophenotyping and cytogenetic and molecular markers in some cases. After clinical examination Lymphomas were diagnosed on the basis of histopathology and Immunohistochemistry of Excised lymph node. Plasma cell dyscrasias were assessed clinically for features of CRAB (hypercalcemia, renal impairment, anemia and lytic lesion) and evaluation was done by hemogram, biochemical parameters and skeletal survey. Later plasma cell dyscrasias was diagnosed on the basis of bone marrow study, Immunofixation electrophoresis, serum free light chain assay, serum protein electrophoresis and myeloma defining events. Ancillary techniques (immunophenotyping, cytogenetics, immunofixation electrophoresis, serum free light chain assay, molecular markers) that were not available in our Institute were outsourced for diagnosis. Clinical information of patients was received from admission file of department of medicine and different laboratory parameters were retrieved from stored data from department of pathology.

Results

In this study, we had 110 cases of hematological neoplasm (HN) from Feb 2015 till Feb 2016. Lymphoid neoplasm was the commonest hematological malignancies with 67 cases (60.9%) followed by myeloid neoplasm of 41 cases (37.3%) and Histiocytic neoplasm of 2 cases (1.5%). Overall median age at diagnosis for all Hematological malignancies was 55 years of age. We have excluded patient of less than 16 years of age.

Lymphoid neoplasm included MBCN 43.6%, ALL 7.3%, HL 5.5% and MTCN 3.6%. In this study, Plasma cell Neoplasm (PCN) (29%) was the commonest lymphoid neoplasm followed respectively by Non Hodgkin Lymphoma (NHL) 14.5%, ALL 7.3%, HL 5.5%, Chronic Lymphocytic Leukemia (CLL) 2.7% and Lymphoplasmacyticy Lymphoma (LPL) 0.9%. NHL includes Diffuse Large B cell Lymphoma (DLBCL)(5.5%), Follicular Lymphoma (FL)(1.8%), Mantle cell Lymphoma (MCL)(0.9%), Marzinal Zone Lymphoma (MZL)(0.9%), Primary Effusion Lymphoma (PEL)(0.9%), Primary Mediastinal B cell Lymphoma (PMBCI)(0.9%), Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) (0.9%), Hepatosplenic T cell Lymphoma (HSTCL) (0.9%), Peripheral T cell Lymphoma (PTCL) (0.9%), Adult T cell Lymphoma (ATCL) (0.9%). (Table 1)
Table 1 Frequency and Distribution pattern of age (years) and sex in Lymphoid Neoplasm

<table>
<thead>
<tr>
<th>H M</th>
<th>110(100%)</th>
<th>10-20</th>
<th>21-40</th>
<th>41-60</th>
<th>&gt;60 years</th>
<th>male</th>
<th>female</th>
<th>M:F</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Lymphoid Neoplasm</td>
<td>66(60%)</td>
<td>110</td>
<td>16(14.5)</td>
<td>31(28%)</td>
<td>18(16.3%)</td>
<td>50(45.4%)</td>
<td>16(14.5)</td>
<td>3:1</td>
</tr>
<tr>
<td>1. Precursor Lymphoid</td>
<td>8(7.2%)</td>
<td>1(0.9%)</td>
<td>4(3.6%)</td>
<td>3(2.7%)</td>
<td>-</td>
<td>7(6.36%)</td>
<td>1(0.9%)</td>
<td>7:1</td>
</tr>
<tr>
<td>a. B-ALL</td>
<td>4(3.6%)</td>
<td>-</td>
<td>3(2.7%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>4(3.6%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b. T-ALL</td>
<td>4(3.6%)</td>
<td>1(0.9%)</td>
<td>1(0.9%)</td>
<td>2(1.8%)</td>
<td>27(24%)</td>
<td>3(2.7%)</td>
<td>1(0.9%)</td>
<td>3:1</td>
</tr>
<tr>
<td>2. MBCN</td>
<td>48(43.6%)</td>
<td>-</td>
<td>3(2.7%)</td>
<td>5(4.5%)</td>
<td>18(16.3%)</td>
<td>36(32.7%)</td>
<td>12(10.9)</td>
<td>3:1</td>
</tr>
<tr>
<td>a. NHL</td>
<td>12(10.9%)</td>
<td>-</td>
<td>3(2.7%)</td>
<td>2(1.8%)</td>
<td>4(3.6%)</td>
<td>8(7.27%)</td>
<td>4(3.6%)</td>
<td>2:1</td>
</tr>
<tr>
<td>a1. FL</td>
<td>2(1.8%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>1(0.9%)</td>
<td>1:1</td>
</tr>
<tr>
<td>a2. MZL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>3(2.7%)</td>
<td>1(0.9%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>a3. DLBCL</td>
<td>6(5.5%)</td>
<td>-</td>
<td>2(1.8%)</td>
<td>-</td>
<td>1(0.9%)</td>
<td>4(3.6%)</td>
<td>2(1.8%)</td>
<td>2:1</td>
</tr>
<tr>
<td>a4. PMBCL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
</tr>
<tr>
<td>a5. PEL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>a6. MCL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>b. LPL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>20(18%)</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
</tr>
<tr>
<td>c. CLL</td>
<td>3(2.7%)</td>
<td>-</td>
<td>-</td>
<td>2(1.8%)</td>
<td>2(1.8%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>2:1</td>
</tr>
<tr>
<td>d. PCN</td>
<td>32(29%)</td>
<td>-</td>
<td>-</td>
<td>12(10.9%)</td>
<td>26(23.6%)</td>
<td>6(5.5%)</td>
<td>-</td>
<td>4:3</td>
</tr>
<tr>
<td>3. MTCN (NHL)</td>
<td>4(3.6%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>a. PCALCL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>4(3.6%)</td>
<td>-</td>
<td>-</td>
<td>3(2.7%)</td>
<td>1(0.9%)</td>
<td>3:1</td>
</tr>
<tr>
<td>b. HSTCL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>c. PTCL, NOS</td>
<td>1(0.9%)</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>d. ATCL</td>
<td>1(0.9%)</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1(0.9%)</td>
<td>-</td>
</tr>
<tr>
<td>4. HL</td>
<td>6(5.5%)</td>
<td>-</td>
<td>5(4.5%)</td>
<td>1(0.9%)</td>
<td>-</td>
<td>4(3.6%)</td>
<td>2(1.8%)</td>
<td>2:1</td>
</tr>
</tbody>
</table>

Among the Myeloid neoplasm (MN), Myeloproliferative neoplasm (MPN) accounted for the maximum number of 9.1% followed by acute myeloid leukemia and precursor neoplasm (AML) of 14.5% then Myelodysplastic syndromes (MDS) 4.5%. AML with recurrent genetic abnormalities were seen in 3.6% whereas AML NOS were 10.9%. In this study, out of 21 MPN cases, Chronic Myeloid Leukemia (CML) were maximum number of cases accounting for 11.8% cases followed by Essential Thrombocythemia (ET) 3.6% and Polycythemia Vera (PV) 1.8% and Primary Myelofibrosis (PM) 1.8%. Among MDS, Refractory cytopenia with unilineage Dysplasia (RCUD) and Refractory Cytopenia with multilineage Dysplasia (RCMD) were equal number of cases that is 1.8% whereas as Refractory Anemia with Excess Blast (RAEB) was 0.9%. (Table 2)
Histiocytic and dendritic cell neoplasm (HDN) accounted for 2 cases (1.5%). Between 2 cases (1.5%) of histiocytic and dendritic Neoplasm were Langerhans cell histiocytosis. We had two Patients less than 20 years of age, T ALL and LCH was seen accounting each 0.9% of HM. In young adult Patient of 21 to 40 years of age, NHL was the most common HM with 9.09% followed by AML 4.5%, MPN (CML) 4.5%, B ALL 2.7%, T ALL 0.9%, and LCH 0.9%. In adults aged 41 to 60 years, MPN 12.6% (CML 6.3%, ET 2.7%, PV1.8%, PM 1.8%) was the most common HM followed respectively by PCN accounting 10.9% followed by AML 4.5%, MPN (CML 4.5%, B ALL 2.7%, T ALL 0.9%, HL 0.9% and LCH 0.9%.

In older patients of more than 61 years of age, PCN was the most common HM accounting 10.9% followed by NHL 3.6%, MDS 2.7%, B ALL 0.9%, HL 0.9%, CL 1.8%, and MDS 1(0.9%).

Hematological malignancies were prevalent more in male than in female. Male accounted for 73.6% and female were 26.4% with male female ratio 2.7:1. In both sex, Lymphoid Neoplasm was most frequent HM followed by Myeloid Neoplasm and Histiocytic Neoplasm.

In males, Lymphoid Neoplasm was most frequent HM with 41.4% followed by Myeloid Neoplasm of 26.3% and Histiocytic Neoplasm accounting 1.8%. Among all these HM, PCN was the most frequent HM with 23.6% followed by MPN 13.57%(CML 7.27%, ET 2.7%, PV 1.8%, PM 1.8%), AML 0.9%, NHL 10% including both B and T phenotype, HL 3.6%, Myelofibrosis 1.8%, MDS 1.8% and CLL 1.8%. However duration of study done was only 1 year and number of cases studied may be low. So, LPL was not seen in male in this study.

In female, Lymphoid Neoplasm was most frequent HM with 16 cases (14.5%) followed by Myeloid Neoplasm of 11.8%. Histiocytic Neoplasm was not seen in female in the study. Among all these Hematological malignancies, NHL, PCN and MPN was the most frequent HM with each 5.5% followed by AML 3.6%, MDS 2.7%, HL 1.8%, CL 1.8%, LPL 0.9% and ALL 0.9%. However, PV and Myelofibrosis was not seen in female in this study.

**Discussion**

This is the first study on Hematological malignancies done in TUTH. It has shown the relative frequencies and distribution of several subtypes of hematological malignancies in different age group and sex. Hematological malignancies were 110 cases in the year February 2015 to January 2016.
In this study overall median age at diagnosis for all Hematological malignancies was 55 years of age. Similarly study done in Eastern morocco also shows median age of 54 years of age. Study done in Bangladesh showed median age of 42 years. It shows there is similar age group involvement in our institute and Morocco. However, in Bangladesh median age is younger.

We have found that overall men are more affected than women, with male to female ratio of 2.7:1. The study done in Eastern Morocco, Bangladesh and Pakistan showed slight male predominance in Hematological malignancies. It has been known that most myeloid and lymphoid are more common in males than females with a justification for this being that men are more likely to be exposed to potentially carcinogenic occupational and environmental agents. In both sex Lymphoid Neoplasm was most frequent HM followed by Myeloid Neoplasm and Histiocytic Neoplasm respectively.

Here, Lymphoid neoplasm was the commonest hematological malignancy with 60.9% followed by myeloid neoplasm 37.3% and Histiocytic neoplasm (LCH) 1.5%. The study done in North America, Australia, Europe and Africa, Eastern morocco and Pakistan also revealed lymphoid neoplasm as the commonest NHL. In Pakistan and US, NHL is the most frequent HM followed respectively by HL, PCN, MPN, AML, MDS, CLL and ALL. In female there is slight similar results seen in these studies however there is different frequencies of HM in Male.

In our study, patient under 20 years of age, T- ALL and LCH was seen each accounting for 0.9% of HM. However, HL has been seen to be the most common HM followed by NHL, AML, MPN and ALL. We had excluded cases under 16 years of age so we had less numbers of cases under 20 years of age in our study. It has been seen that Precursors T- and B- cell malignancies are primarily diseases of children and young adults.

In young adult Patient of 21 to 40 years of age, NHL was the most common HM with 9.09% followed by AML 4.5%, MPN (CML) 4.5%, B ALL 2.7%, T ALL 0.9%, HL 0.9% and LCH 0.9%. The study done in Eastern Moroccan showed HL as the most frequent HM in this age group followed by respectively by NHL, MPN, AML, ALL and MM, CLL, MDS and WM. In our study NHL was the most frequent HM whereas other study showed HL as the commonest HM. In Bangladesh, AML has been commonly seen at this age group.

In adults aged 41 to 60 years, MPN 12.6% (CML 6.3%, ET 2.7%, PV1.8%, PM1.8%) was the most common HM followed respectively by PCN accounting 10.9% followed by AML 7.2%, NHL 4.5%, MDS 3.6%, ALL 1.8%, HL 0.9%,CLL 1(0.9%) and LPL 1(0.9%). In this age group other study showed NHL was predominant HM followed by MPN, MM, HL, CLL, AML, MDS, ALL and WM. In our study MPN and PCN was the commonest HM in this age group whereas other study showed NHL as the commonest HM. CLL, MDS and PCN has been reported as common Hematological malignancies in this age group. Hematological malignancies arising from mature immunocompetent cells (mostly B lineage) predominate in adults. A variation in hematological malignancies with age suggests that immune system rich in precursor cells in young people and predominance of germinal centre and memory B cells in older adults.

In older patients of more than 61 years of age, PCN was the most common HM accounting 10.9% followed by NHL 3.6%, AML 2.9%, CLL 1.8%, MPN 1.8%(CML 0.9%, ET 0.9%) and MDS 1(0.9%). One of the study showed NHL as the most common HM followed by MM, MPN, CLL,
Our study shows PCN is the commonest HM whereas other study showed NHL as the commonest HM. It has been observed that in northern India; PCN (multiple myeloma) is more common in older age group with median age of 61 years. 

**Conclusion**

Hematological malignancies can occur at any age group and men are more commonly affected. Lymphoid neoplasm is the most frequent HM. NHL is the most common HM in young adults whereas PCN is the most common HM in elderly. Hematological malignancies arising from Precursors T and B cells are common in children and adolescents where as Lymphoid Neoplasm arising from germinal centre and memory B cells are common in adults.

**References**


